Completed PHASE4 INTERVENTIONAL 1-arm NCT02878564

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology

Sponsor: UVRI-IAVI HIV Vaccine Program, Uganda

Updated 5 times since 2017 Last updated: Oct 26, 2016 Started: Mar 31, 2016 Primary completion: Oct 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV and Schistosomiasis Mansoni, this trial is completed. The trial is conducted by UVRI-IAVI HIV Vaccine Program, Uganda and has accumulated 5 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UVRI-IAVI HIV Vaccine Program, Uganda
University of Toronto

Data source: University of Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Entebbe, Uganda